Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nippon Shinyaku Chief Defends Benefits of DMD Therapy after PIII Miss
Despite its failure in a key confirmatory trial, Viltepso (viltolarsen) remains a “meaningful” option for patients with Duchenne muscular dystrophy (DMD), Toru Nakai, president of the drug’s manufacturer Nippon Shinyaku, said on May 28. “It’s disappointing that the drug could…
To read the full story
Related Article
BUSINESS
- Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
- Nxera Bags US$10 Million Milestone from AbbVie in Neuro Collaboration
April 21, 2026
- Asahi Kasei Closes Aicuris Buy, Eyes US$500 Million Sales by 2030
April 21, 2026
- 3D Slams Toho’s Info Requests as Bid to Justify Defense Measures
April 21, 2026
- Mitsui Fudosan, LINK-J, SS-F Launch Rental Lab Hub in Yokohama
April 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…